Pardes Biosciences, Inc.
Pardes BioSciences, Inc. uses COVID-19 research approach involving direct acting antivirals.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
$75.0m Valuation: $250m | SPAC Private Placement | ||
| Total Funding | 000k | ||
Khosla Ventures(exited)
Gilead Sciences(exited)
RA Capital Management(exited)
Frazier Healthcare Partners(exited)
Foresite Capital(exited)
Y Combinator(exited)
Olive Capital(exited)
Frazier Life Sciences(exited)
| USD | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.